Region
CDMOs in Asia
Compare Asian CDMOs across India, China, Japan, South Korea, and Southeast Asia. Filter by manufacturing type, regulatory approvals, and capacity for API synthesis, biologics, and drug products.
707 companies listed
Asian CDMO Manufacturing
Asia is the fastest-growing CDMO market, led by India (API synthesis powerhouse), China (increasingly sophisticated biologics and small molecule capabilities), South Korea (biosimilar manufacturing leader), and Japan (high-quality specialty manufacturing). Together, Asian CDMOs produce an estimated 60-80% of the world's active pharmaceutical ingredients.
India dominates small molecule API manufacturing. The country has over 3,000 pharmaceutical manufacturing facilities, many FDA-inspected, producing APIs for global generics markets. Indian CDMOs offer 30-50% cost advantages over Western alternatives for chemical synthesis. However, quality varies significantly -- due diligence on facility inspection history and quality systems is essential.
South Korea and Japan represent the premium end of Asian CDMO manufacturing. Samsung Biologics and Celltrion in South Korea have built world-class biologics facilities (up to 360,000L combined capacity). Japanese CDMOs (AGC Biologics' Chiba facility, FUJIFILM Diosynth) offer exceptional quality systems and specialized capabilities. China's WuXi Biologics and WuXi AppTec, though affected by BIOSECURE Act uncertainty, remain major global players.
Browse Asia CDMOs by country
Every country below has its own page with a ranked CDMO list, a country-zoomed facilities map, and the local regulatory picture. Counts are live manufacturing-site totals.
Companies (707)
bitBiome, Inc.
Japan
bitBiome Inc. is a Japanese biotechnology startup based in Tokyo that specializes in sequencing, cataloging, and evolving microbial genomes using single-cell genomics. The company has a strategic partnership with a CMO for manufacturing and supply of products but does not itself operate as a contract manufacturer. bitBiome focuses on discovering novel enzymes and proteins from microbial diversity for industrial and pharmaceutical applications.
BLi-T (Hefei) Chemical Co., Ltd.
China
BLi-T (Hefei) Chemical Co., Ltd. is a Chinese chemical supplier offering a wide range of products including cosmetic raw materials, fine chemicals, water treatment chemicals, vitamins, food additives, solvents, pharmaceutical chemicals, and agricultural chemicals. The company provides customized production and has advanced manufacturing processes including nitration, sulfonation, halogenation, hydrogenation, fermentation, and enzyme catalysis. BLi-T is a raw material and chemical supplier, not a pharmaceutical CDMO.
Frequently Asked Questions
What are the risks of manufacturing with Asian CDMOs?+
Key risks include: regulatory uncertainty (BIOSECURE Act affects certain Chinese CDMOs), longer supply chains increasing transit times and cold chain risks, time zone differences complicating project management, intellectual property protection concerns (varies by country -- Japan and South Korea have strong IP; others require careful contractual protections), and quality system variability requiring thorough site audits before engagement.
Which Asian countries lead in different manufacturing types?+
India leads in small molecule API synthesis and generic drug product manufacturing. South Korea dominates commercial-scale biosimilar production. Japan excels in specialty biologics, ADCs, and high-potency compounds. China has broad capabilities across small molecules, biologics, and cell therapy, with rapidly improving quality infrastructure. Singapore is emerging as a gene therapy and advanced manufacturing hub.
Related Categories
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
